FDx Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $322K | Sell |
350
-23
| -6% | -$23.3K | 0.1% | 127 |
|
|
2025
Q4 | $401K | Buy |
+373
| New | +$357K | 0.2% | 53 |
|
|
2025
Q3 | – | Sell |
-359
| Closed | -$280K | – | 192 |
|
|
2025
Q2 | $280K | Sell |
359
-40
| -10% | -$31.1K | 0.09% | 139 |
|
|
2025
Q1 | $330K | Sell |
399
-32
| -7% | -$26.6K | 0.11% | 116 |
|
|
2024
Q4 | $333K | Sell |
431
-71
| -14% | -$58.8K | 0.1% | 127 |
|
|
2024
Q3 | $445K | Sell |
502
-18
| -3% | -$16.2K | 0.12% | 115 |
|
|
2024
Q2 | $471K | Sell |
520
-8,664
| -94% | -$6.93M | 0.13% | 104 |
|
|
2024
Q1 | $7.14M | Sell |
9,184
-1,456
| -14% | -$1.04M | 1.08% | 16 |
|
|
2023
Q4 | $6.2M | Sell |
10,640
-3,129
| -23% | -$1.83M | 0.48% | 46 |
|
|
2023
Q3 | $7.4M | Sell |
13,769
-9,093
| -40% | -$4.69M | 0.61% | 38 |
|
|
2023
Q2 | $10.7M | Sell |
22,862
-4,614
| -17% | -$1.93M | 0.59% | 37 |
|
|
2023
Q1 | $10.1M | Hold |
27,476
| – | – | 0.44% | 59 |
|
|
2022
Q4 | $10.1M | Buy |
27,476
+243
| +0.9% | +$86.2K | 0.44% | 59 |
|
|
2022
Q3 | $8.81M | Sell |
27,233
-4,216
| -13% | -$1.34M | 0.39% | 58 |
|
|
2022
Q2 | $10.2M | Sell |
31,449
-3,418
| -10% | -$1.03M | 0.38% | 57 |
|
|
2022
Q1 | $9.98M | Sell |
34,867
-9,955
| -22% | -$2.56M | 0.34% | 62 |
|
|
2021
Q4 | $12.4M | Buy |
44,822
+1,553
| +4% | +$394K | 0.34% | 66 |
|
|
2021
Q3 | $10M | Buy |
43,269
+1,486
| +4% | +$367K | 0.32% | 65 |
|
|
2021
Q2 | $9.59M | Buy |
41,783
+4,749
| +13% | +$954K | 0.32% | 71 |
|
|
2021
Q1 | $6.92M | Sell |
37,034
-4,834
| -12% | -$946K | 0.26% | 88 |
|
|
2020
Q4 | $7.07M | Sell |
41,868
-1,228
| -3% | -$183K | 0.29% | 83 |
|
|
2020
Q3 | $6.38M | Buy |
43,096
+11,585
| +37% | +$1.79M | 0.3% | 78 |
|
|
2020
Q2 | $5.17M | Buy |
31,511
+4,561
| +17% | +$700K | 0.27% | 80 |
|
|
2020
Q1 | $3.74M | Buy |
26,950
+6,718
| +33% | +$923K | 0.24% | 92 |
|
|
2019
Q4 | $2.66M | Buy |
20,232
+7,416
| +58% | +$860K | 0.15% | 126 |
|
|
2019
Q3 | $1.43M | Sell |
12,816
-1,911
| -13% | -$213K | 0.1% | 168 |
|
|
2019
Q2 | $1.63M | Buy |
14,727
+780
| +6% | +$91.9K | 0.06% | 227 |
|
|
2019
Q1 | $1.81M | Buy |
13,947
+1,161
| +9% | +$141K | 0.07% | 194 |
|
|
2018
Q4 | $1.48M | Sell |
12,786
-362
| -3% | -$40.4K | 0.12% | 129 |
|
|
2018
Q3 | $1.41M | Sell |
13,148
-2,079
| -14% | -$208K | 0.05% | 274 |
|
|
2018
Q2 | $1.3M | Sell |
15,227
-27,579
| -64% | -$2.27M | 0.05% | 315 |
|
|
2018
Q1 | $3.31M | Sell |
42,806
-26,122
| -38% | -$2.1M | 0.1% | 167 |
|
|
2017
Q4 | $5.82M | Sell |
68,928
-20,624
| -23% | -$1.75M | 0.16% | 104 |
|
|
2017
Q3 | $7.66M | Buy |
89,552
+111
| +0.1% | +$9.1K | 0.21% | 84 |
|
|
2017
Q2 | $7.36M | Sell |
89,441
-11,675
| -12% | -$952K | 0.22% | 77 |
|
|
2017
Q1 | $8.51M | Sell |
101,116
-1,829
| -2% | -$146K | 0.26% | 74 |
|
|
2016
Q4 | $7.57M | Buy |
102,945
+21,939
| +27% | +$1.63M | 0.22% | 90 |
|
|
2016
Q3 | $6.5M | Sell |
81,006
-712
| -0.9% | -$57K | 0.27% | 65 |
|
|
2016
Q2 | $6.43M | Sell |
81,718
-2,471
| -3% | -$186K | 0.29% | 70 |
|
|
2016
Q1 | $6.06M | Buy |
84,189
+3,027
| +4% | +$229K | 0.28% | 71 |
|
|
2015
Q4 | $6.84M | Buy |
81,162
+8,419
| +12% | +$699K | 0.31% | 67 |
|
|
2015
Q3 | $6.09M | Buy |
72,743
+915
| +1% | +$77.2K | 0.52% | 34 |
|
|
2015
Q2 | $6M | Sell |
71,828
-5,972
| -8% | -$455K | 0.3% | 63 |
|
|
2015
Q1 | $5.65M | Buy |
77,800
+17,593
| +29% | +$1.25M | 0.12% | 149 |
|
|
2014
Q4 | $4.15M | Sell |
60,207
-11,448
| -16% | -$773K | 0.25% | 68 |
|
|
2014
Q3 | $4.65M | Buy |
71,655
+16,930
| +31% | +$1.07M | 0.3% | 57 |
|
|
2014
Q2 | $3.4M | Buy |
54,725
+11,370
| +26% | +$678K | 0.22% | 95 |
|
|
2014
Q1 | $2.55M | Buy |
+43,355
| New | +$2.42M | 0.21% | 103 |
|
Other funds holding LLY
VCM
VPM
FDx Advisors's LLY Position: Q1 2026 in Review
FDx Advisors reduced its Eli Lilly (LLY) stake by 6.2% in Q1 2026, selling an estimated $23.3K and leaving 350 shares worth $322K. The position accounts for 0.1% of the portfolio, ranked #127.
FDx Advisors first reported a position in LLY in Q1 2014 and has held it in 48 quarters since. The position peaked at $12.4M in Q4 2021. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- FDx Advisors held 350 shares of Eli Lilly worth $322K as of Q1 2026.
- FDx Advisors sold 23 Eli Lilly shares in Q1 2026, an estimated $23.3K.
- Eli Lilly made up 0.1% of FDx Advisors's portfolio in Q1 2026, its #127 holding.
- FDx Advisors first reported a position in Eli Lilly in Q1 2014 and has held it in 48 quarters since.
- FDx Advisors's Eli Lilly position peaked at $12.4M in Q4 2021.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on FDx Advisors's 13F filing for Q1 2026, filed 1 May 2026.